For the Inventor, By the Inventor

Enter assignee name

Poxel

USPTO Granted Patents = 13

CIPO Patents = 3

EPO Patents = 14

Trademarks = 2

Forward Citations = 27

Loading Chart...

Loading Chart...

32 inventors (with patents filed for the assignee):

Daniel Cravo (9 out of 26 patents)

Sophie Hallakou-Bozec (7 out of 14 patents)

Sébastien Bolze (6 out of 11 patents)

4. Pascale Fouqueray (3 out of 3 patents)

5. Jean-Denis Durand (2 out of 6 patents)

6. Amaury Patin (2 out of 5 patents)

7. Franck F Lepifre (2 out of 12 patents)

8. Patrice Andre (2 out of 37 patents)

9. Pauline Radreau (2 out of 2 patents)

10. Vincent Lotteau (2 out of 10 patents)

11. Marine Gilardone (2 out of 2 patents)

12. Christine G Charon (2 out of 28 patents)

13. Laurent Faveriel (2 out of 2 patents)

14. Didier Mesangeau (2 out of 13 patents)

15. Matthias Helmreich (2 out of 3 patents)

13 patents: Sort by Forward Citations

1. 12319700 - Monohydrate potassium salt of a thienopyridone derivative and its preparation process (2025-06-03),

2. 12310949 - Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (ADPKD) (2025-05-27),

3. 11850238 - Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy (2023-12-26),

4. 10071108 - Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection (2018-09-11),

5. 9895380 - Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection (2018-02-20),

6. 9365584 - Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof (2016-06-14),

7. 9284329 - Thienopyridone derivatives useful as activators of AMPK (2016-03-15),

8. 9271984 - Treatment of type 1 diabetes (2016-03-01),

9. 9035048 - Tetrahydrotriazine compounds for treating diseases associated with AMPK activity (2015-05-19),

10. 8937066 - Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases (2015-01-20),

11. 8846911 - Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization (2014-09-30),

12. 8742103 - Separation of triazine derivatives enantiomers using tartaric acid (2014-06-03),

13. 8742102 - Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization (2014-06-03),

Poxel is a biopharmaceutical company focused on the development of innovative treatments for metabolic diseases, including type 2 diabetes. Their pipeline includes novel drug candidates that target key cellular functions involved in glucose and energy metabolism. Poxel is driven by a commitment to improving the lives of patients through cutting-edge research and development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

13 Patents

#24 in Lyons

#1,369 in France

#43,688 in the World

Poxel

Forward Citations = 27

32 inventors:

Daniel Cravo (9 out of 26 patents)

Sophie Hallakou-Bozec (7 out of 14 patents)

Sébastien Bolze (6 out of 11 patents)

4. Pascale Fouqueray (3 out of 3 patents)

5. Jean-Denis Durand (2 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…